TrialThe Lancet. Haematology2015

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.

Jun Imagawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.